null

null

null

null

null

null

null

null

null

null

null

null

null

null

1.75x Total Debt / Equity (Elevated leverage)

Minimal debt leverage; cash-burning clinical-stage biotech funded by equity, so rate changes affect treasury yield on cash reserves more than debt servicing

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Oligopoly of oligonucleotide/spherical nucleic acid synthesis suppliers; single-source HDAC inhibitor conjugation chemistry vendors concentrated in North America and Europe

Negligible international revenue; clinical-stage US-based company with no material foreign currency exposure in top markets

Effectively zero sovereign currency devaluation risk; operations and trials US-domiciled with no material international revenue streams

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on Exicure's proprietary SNA platform and select CRO/CMO partners; single-source oligonucleotide manufacturers likely exceed 30% of operational input cost

Clinical-stage biopharmaceutical; revenue model is collaboration/licensing agreements, not cloud-dependent SaaS; AWS termination would disrupt data systems but not core drug development irreparably

Preclinical and clinical research operations rely on CRO partnerships and lab informatics; cloud disruption recoverable within 60-90 days via alternative providers

Low API coupling risk; company uses standard bioinformatics and lab data platforms without deep proprietary API integration dependencies

Not applicable; primary revenue is pharma licensing/collaboration, not a token or investment contract scheme; Howey Test risk is negligible

Very High

Moderate HIPAA exposure from clinical trial patient data; limited GDPR risk given minimal EU trial activity; CCPA exposure low given no consumer-facing products

Negligible antitrust risk; small-cap clinical-stage company with no dominant market position in any therapeutic area

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% transactional/milestone-based from collaboration agreements; no recurring subscription revenue; Allergan/AbbVie partnership milestones were primary historical revenue source

Upfront licensing fees plus development milestones and royalties; entirely dependent on partnership deal flow and clinical advancement triggers

Pricing determined by negotiated licensing terms with large pharma partners; no direct product pricing architecture; royalty rates typically 5-15% of net sales industry norm

Weak standalone pricing power; entirely dependent on partner negotiations and competitive landscape for SNA-based therapeutics licensing

Collaboration revenue near 100% gross margin when recognized; but R&D burn far exceeds revenue, making effective margin deeply negative (-300% to -500% of revenue)

No free-rider problem; proprietary SNA IP platform is protected; risk is partnership termination (AbbVie terminated collaboration 2022), not IP leakage

Headcount-linear to sublinear at current stage; doubling pipeline programs requires proportional scientific staff increases; no meaningful operating leverage until commercialization

Marginal cost of advancing each additional IND is high (~$5-15M per program); growth is not scalable without partner capital; capital-intensive per program

Not applicable; company has no franchise network

At 10x scale, unit economics depend on royalty-bearing product approvals; customer acquisition cost is irrelevant; partnership deal cost is years of R&D (~$50-100M+ per asset)

No network effects; proprietary SNA platform has scientific defensibility but value does not compound with additional users or data nodes

-39.7% Return on Assets (Negative equity)

Low recession resistance; clinical-stage biotech dependent on capital markets and partner R&D budgets, both of which contract sharply in recessions

Large pharmaceutical/biopharmaceutical companies seeking novel oligonucleotide delivery platform licensing (e.g., AbbVie historically)

Government and academic research grants (NIH-funded); secondary but meaningful non-dilutive funding source for early-stage programs

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital being consumed to sustain legacy pipeline with no clear reallocation to future-state infrastructure; company underwent significant restructuring in 2022-2023 reducing headcount and programs

0001698530

XCUR